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The proportion of patients undergoing liver trans-
plantation (LT), with concomitant renal dysfunction,
markedly increased after allocation by the model for
end-stage liver disease (MELD) score was introduced.
We examined the incidence of subsequent post-LT
end-stage renal disease (ESRD) before and after the
policy was implemented. Data on all adult deceased
donor LT recipients between April 27, 1995 and De-
cember 31, 2008 (n = 59 242), from the Scientific Reg-
istry of Transplant Recipients, were linkedwith Centers
for Medicare & Medicaid Services’ ESRD data. Cox re-
gression was used to (i) compare pre-MELD and MELD
eras with respect to post-LT ESRD incidence, (ii) deter-
mine the risk factors for post-LT ESRD and (iii) quantify
the association between ESRD incidence and mortal-
ity. Crude rates of post-LT ESRDwere 12.8 and 14.5 per
1000 patient-years in the pre-MELD andMELD eras, re-
spectively. Covariate-adjusted post-LT ESRD risk was
higher in the MELD era (hazard ratio [HR] = 1.15;
p = 0.0049). African American race, hepatitis C, pre-
LT diabetes, higher creatinine, lower albumin, lower
bilirubin and sodium>141mmol/L at LT were also sig-
nificant predictors of post-LT ESRD. Post-LT ESRD was
associated with higher post-LT mortality (HR = 3.32;
p < 0.0001). The risk of post-LT ESRD, a strong predic-
tor of post-LT mortality, is 15% higher in the MELD era.
This study identified potentially modifiable risk factors
of post-LT ESRD. Early intervention and modification
of these risk factors may reduce the burden of post-LT
ESRD.
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Introduction
Posttransplant chronic renal failure is a major posttrans-
plant comorbidity among nonrenal solid organ transplant
recipients and is associated with high mortality (1). Among
nonrenal solid organ transplant recipients in the allocation
era, before the use of the model for end-stage liver dis-
ease (MELD), liver transplant (LT) recipients had the second
highest incidence of posttransplant chronic renal failure,
despite lower level of immunosuppression with calcineurin
inhibitors, compared to the heart and lung transplant
recipients (1).
The MELD score, a measure of waiting list mortality risk,
has been used as the basis of deceased-donor liver allo-
cation since February 2002 and serum creatinine is one
of the key components of the MELD score. Our previous
research showed that serum creatinine is given excess
weight in the current MELD formula (2). Not surprisingly,
the proportion of patients undergoing LTwith pretransplant
renal dysfunction significantly increased in the MELD era
compared to the pre-MELD era (3). Moreover, MELD is
unable to distinguish between renal dysfunction due to
acute and potentially reversible kidney injury, secondary to
hepatorenal syndrome or due to chronic kidney disease,
secondary to hypertension or diabetes.
We previously conducted a single-center MELD-era cohort
study that estimated the 5-year cumulative incidence of
post-LT chronic renal failure to be 22% (4). However, that
study did not focus on end-stage renal disease (ESRD), and
also did not have a pre-MELD comparison group. In the
current study, we linked national data from the Scientific
Registry of Transplant Recipients (SRTR) and the Centers
for Medicare & Medicaid Services (CMS) ESRD program
to determine the impact of MELD-based allocation on the
incidence of new-onset ESRD among LT recipients. We
also sought to determine donor and recipient risk factors
associated with new-onset post-LT ESRD as well as evalu-
ate the relationship between new-onset ESRD and post-LT
mortality.
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Methods
Data sources and study population
Our study was based on data obtained from the SRTR, the CMS ESRD
program and the Social Security DeathMaster File (5). The SRTRmaintains a
database of all candidates for and recipients of solid organ transplants in the
United States. Patients on waiting lists for organ transplantation and those
who receive organ transplants are followed on a periodic basis with the use
of data collection forms completed by organ-transplantation programs and
submitted to the Organ Procurement and Transplantation Network. These
follow-up data, in addition to data from the network regarding patients
on waiting lists and the allocation of organs, are included in the SRTR
database. The SRTR supplements information on vital status with data
on deaths from the Social Security Death Master File and the Medicare
Beneficiary Database maintained by CMS. Data collection by the SRTR
is exempt from oversight under the “public benefit or service program”
provisions of the Code of Federal Regulations (45 CFR 46.101[b][5]), as
approved by the institutional review board of the Health Resources and
Services Administration of the Department of Health and Human Services.
The Social Security Death Master File includes updated information on all
participants in the Social Security system. Information on deaths reported
to the Social Security system for the administration of the death, disability
and retirement benefit programs is kept in the Death Master File database.
CMS maintains a database of all patients treated for ESRD in the United
States, that includes information about demographics, treatment, hospital-
ization and costs for Medicare beneficiaries and other patients with ESRD
who have received maintenance renal replacement therapy (RRT). This
database also includes records of any changes in vital status or method
of renal replacement, including kidney transplantation (6). Our study pop-
ulation included candidates 18 years of age and older who received LT
between April 27, 1995 and December 31, 2008 (n = 59 242). Living donor
andmultiorgan transplants were excluded. The time period was divided into
pre-MELD and MELD eras. Patients who received LT before February 28,
2002 were assigned to the pre-MELD era, and those who received LT on
or after February 28, 2002 were assigned to the MELD era.
We constructed an analysis file containing information on the baseline de-
mographic and clinical characteristics of the LT recipients who met inclu-
sion criteria. The analysis file was linked to the CMS ESRD database to
identify patients who received RRT after transplantation of the liver. The
linkage between SRTR data and CMS data was established by matching
patient-level sources, finding similarities in patient identifiers such as social
security numbers, health insurance claim number, names and nicknames,
gender and date of birth. More information on the nature of such linkages
is described by Dickinson et al. (6).
Analytical approach
In the descriptive analysis, continuous variables were expressed as mean ±
standard deviation and categorical variables were expressed as proportions.
The primary outcome was new-onset post-LT ESRD, defined as the earliest
of initiation of chronic dialysis, wait listing for kidney transplantation and re-
ceipt of a kidney transplant ascertained by the CMS 2728 medical evidence
form. This form is completed by the patient’s dialysis center within 45 days
of initiation of chronic dialysis or receipt of kidney transplantation. The listing
for renal transplantation was ascertained from the SRTR data. These are
objective and well-defined outcomes captured in the CMS ESRD and SRTR
databases. Note that the CMS 2728 form is not completed if the patient
is in acute renal failure or is expected to recover renal function. Therefore,
a patient who requires dialysis for some period of time, after transplanta-
tion but recovers their renal function would not be included in the CMS
ESRD database. Similarly, patients who receive continuous veno-venous
hemodialysis or a few courses of RRT in the immediate posttransplant
phase would not be included in the CMS ESRD database. Patients in the
acute phase of renal failure are not listed for kidney transplantation and,
therefore, would not be in the data set either. Since, we are looking at post-
LT ESRD as a primary outcome and because listing of kidney transplant
is a surrogate for RRT, we included both initiation of chronic dialysis and
listing for kidney transplantation as our outcome. The date of placement on
the waiting list for kidney transplantation was tracked for patients with liver
transplants in whom, ESRD subsequently developed. Renal replacement
modality changes from dialysis to renal transplantation were also recorded
in order to identify patients who received a renal transplant from either a
living or deceased donor.
Patients were followed from the date of LT to the earliest of new-onset
ESRD, death or the end of observation period. The incidence rate was
calculated as the number of ESRD events divided by total patient time
expressed as patient-years.
Given the available data structure and our objectives, death (before ESRD
onset) was treated as a competing risk; i.e. since, post-LT death precludes
post-LT new-onset ESRD. Therefore, wemodeled the cause-specific hazard
of ESRD (7), which can be thought of as the rate of ESRD incidence among
patients alive and ESRD-free. An alternative approach would be to model
the cumulative incidence of ESRD, which can be thought of as the follow-up
time-specific probability of ESRD (acknowledging that ESRD onset cannot
occur following death 0. The cumulative incidence of ESRD essentially
averages over deceased and surviving patients and, hence, would be most
useful for descriptive purposes.
In the first part of the analysis, Cox regression was used to contrast the
pre-MELD and MELD eras with respect to ESRD incidence, adjusting for
recipient’s age, gender, race, diagnosis, height, weight, status, pre-LT hyper-
tension, diabetes, hospital status at LT, previous LT, history of transjugular
intrahepatic portosystemic shunt (TIPS), donor age, donor gender, cold is-
chemia time, local versus (regionally, nationally) shared organ and donation
after cardiac death (DCD) and the type of immunosuppression. We fitted
one model in contrast to covariate-adjusted ESRD incidence rates between
the two eras. We, then fitted a second model that coded the year of trans-
plant as a continuous predictor (to test for a trend over calendar time), but
with a change-point at year 2002 (to test for a change in the trend beginning
in 2002, the start of MELD-based allocation).
In the second part of the analysis, Cox regressionwas used to determine the
risk factors for new-onset post-LT ESRD among LT recipients. In this case,
only patients transplanted in theMELD era whowere not on RRT at LTwere
used, because lab measurements (i.e. creatinine, bilirubin, INR, albumin)
were generally not available in the pre-MELD era. The model was adjusted
for all covariates listed above, plus bilirubin, international normalized ratio
(INR), creatinine, change in creatinine pre-LT (slope), sodium and albumin at
LT. The slope of creatinine was estimated using least squares regression,
(i.e. the familiar slope estimator from simple linear regression) based on all
available creatinine values from the time of wait listing to the time of LT.
The MELD score update is a complex process. Serum bilirubin, creatinine
and INR are components of the MELD score. For some candidates, it could
be one MELD update (creatinine values) between listing and transplant
while for others it could be close to 10–15 or greater MELD updates, (each
including a creatinine value) available to calculate the slope.
As implied previously, we fitted proportional hazards models to the cause-
specific hazard of ESRD. This was carried out using PROC PHREG in SAS
v9.2 (SAS Institute, Cary, NC, USA). In particular, the input record for each
patient was the covariate; time between LT and the earliest of death, ESRD,
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Table 1: Cohort characteristics at the time of liver transplantation
by era
Pre-MELD era MELD era
Variables (n = 25 500) (n = 33 742)








Hepatitis C 43% 44%
Fulminant hepatic failure 7% 7%
Donor age (years) 37.6 (17.5) 41.4 (17.5)
Cold ischemia time (hours) 8.6 (3.9) 7.5 (3.5)
loss to follow-up and end of study (with loss to follow-up and end of study,
both treated as independent censoring); and an event indicator taking the
value 1 for ESRD and 0 for either censoring or death. Note that the grouping
of loss to follow-up, end of study and death as event = 0 should not be
mistaken for an assumption that death and ESRD are independent. Coding
all these events as event = 0 is merely a computational trick to make
PHREG compute the risk sets appropriately. Putter et al. provide an excellent
summary of related issues in the competing risks setting (8).
For the third component of the analysis, a time-dependent Cox model was
used to study the association between post-LT ESRD and mortality, with
ESRD (yes/no) coded as a time-dependent binary indicator.
As a subanalysis, we also modeled the rate of death before ESRD onset
(i.e. cause-specific hazard of death among patients alive and ESRD-free),
again using Cox regression. This model complements the first part of the
analysis, in the sense that patients can cease to be alive and ESRD-free via
two mutually exclusive events: ESRD onset (modeled in the first part of the
analysis) and death before ESRD (the subanalysis).
All statistical analyses were conducted using SAS v9.2 (SAS Institute).
Results
Descriptive statistics
The study cohort consisted of 59 242 LT recipients (pre-
MELD era: n= 25 500 andMELD era: n= 33 742). Baseline
characteristics of LT recipients were similar in both eras
(Table 1). On an average, LT recipients in the pre-MELD era
received younger donor allografts with slightly longer cold
ischemia time. Information on serum bilirubin, creatinine,
INR, albumin and sodium were not available in the pre-
MELD era.
Post-LT ESRD incidence rates and era effect
There were a total of 1878 and 1156 ESRD events in the
pre-MELD and MELD eras, respectively. The unadjusted
incidence rate of post-LT ESRD was 12.8 per 1000 patient-
years in the pre-MELD era and 14.5 per 1000 patient-years
in the MELD era.
LT in the MELD-based allocation era was associated with
a 15% higher risk of post-LT ESRD compared to the pre-
MELD era (hazard ratio [HR] = 1.15; 95% confidence inter-
val 1.043–1.268; p = 0.0049), based on a Cox regression
model adjusted for recipient’s age, gender, race, diagno-
sis, height, weight, status, pre-LT hypertension, diabetes,
hospital status at LT, previous LT, history of TIPS, donor
age, donor gender, cold ischemia time, local versus (re-
gionally, nationally) shared organ and DCD and the type of
immunosuppression.
Figure 1 displays trends in covariate-adjusted post-LT ESRD
incidence by calendar year of LT. Before 2002 (pre-MELD
era), rates of new-onset post-LT ESRD decreased signifi-
cantly by 5.1%per year (HR= 0.949; 95%confidence inter-
val 0.924–0.975; p < 0.0001). However, the trend sharply
reversed in 2002 (MELD era), with ESRD incidence increas-
ing by 7.6% per year after year 2002 (p < 0.0001).
Subanalysis revealed that post-LT mortality (among pa-
tients alive and ESRD-free) was significantly 10% lower
in the MELD era (covariate adjusted HR = 0.902; 95%
confidence interval 0.864–0.941; p < 0.0001) relative to
the pre-MELD era.
Predictors of post-LT ESRD in the MELD era
Table 2 shows recipient and donor risk factors associated
with new-onset post-LT ESRD in the MELD era. African
American race (HR = 1.57, p < 0.0001), history of dia-
betes (HR = 2.20, p < 0.0001), hepatitis C as an etiology
of liver disease (HR = 1.34, p < 0.0003), high serum cre-
atinine at the time of LT (HR = 4.08, p < 0.0001), serum
sodium >141 mmol/L (HR = 1.42, p < 0.0034), low albu-
min (HR = 0.53, p < 0.0001), low bilirubin (HR = 0.83,
p < 0.0001), history of TIPS (HR = 1.40 p = 0.0013) and
history of previous LT (HR = 1.49, p = 0.0012) were the
recipient factors associated with higher risk of new-onset
post-LT ESRD. A larger increase in creatinine slope over
time before LT (change in creatinine from listing to LT) was
associated with a lower risk of post-LT ESRD compared
to those with a smaller increase in pre-LT creatinine slope
(HR = 0.86; p < 0.0001). INR, one of the components
of MELD score, was not associated with post-LT ESRD in
the MELD era (HR = 0.86; 95% confidence interval 0.691–
1.072; p = 0.146).
Donor factors associated with higher risk of new-onset
post-LT ESRD included age 50–69 years, male gender and
DCD donor. Longer cold ischemia time was associated
with higher risk of new-onset post-LT ESRD (Table 2). Nei-
ther, the type of calcineurin inhibitor nor use of antibody
induction after LT affected the risk of new-onset post-LT
ESRD.
Effect of post-LT ESRD on patient survival
Post-LT mortality increased more than threefold upon
onset of ESRD, with covariate-adjusted HR = 3.32
(p < 0.0001), as shown in Table 3. Other recipient and
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Figure 1: The risk of post-LT ESRD by the year of liver transplant. X-axis shows the year of liver transplantation and Y-axis shows
the hazard ratio of post-LT ESRD. The hazard ratio for the year of liver transplantation was obtained from the regression model. Hazard
ratio = explin pred and lin pred = ln(0.949) × (YEAR-1995) + ln(1.134) × (YEAR-2002) × I(Year > 2002).
donor factors predicting post-LT mortality are also listed in
Table 3.
Discussion
We are not aware of any prior study that has directly evalu-
ated the impact of MELD-based liver allocation on the risk
of new-onset post-LT ESRD. Our results indicated a 15%
higher risk of post-LT ESRD in the MELD era compared
to the pre-MELD era, independent of the various modi-
fiable and nonmodifiable recipient and donor risk factors
that were also associated with new-onset post-LT ESRD.
Importantly, post-LT ESRD incidence rates were on the
decline until MELD-based allocation took effect in 2002,
after which the rates sharply reversed trend and began
to increase significantly. The declining rates of ESRD in
LT patients in the pre-MELD era could be a combination of
centers not transplanting candidates with severe renal dys-
function (known to be associated with worse outcomes),
as well as change in immunosuppression practice patterns
from cyclosporine, (which is associated with slightly higher
risk of post-LT chronic renal failure [HR = 1.25, p < 0.001])
to tacrolimus after 1994 (1,9).
Compared to the pre-MELD era, post-LT mortality was
10% lower in the MELD era among those who did not de-
velop ESRD. This era effect reflects evolution of the field in
terms of better medical and surgical patient management,
better diagnostic and interventional techniques and ad-
vancement in immunosuppression (9). However, once the
ESRD developed, risk of post-LT death increased threefold
in our study. Although the post-LT ESRD incidence rates
showed an absolute change from 12.8 per 1000 patient-
years to 14.5 per 1000 patient-years in the pre-MELD era
and MELD era, respectively, this 21% relative increase in
post-LT ESRD incidence rates and 15% higher risk of de-
veloping post-LT ESRD in the MELD era compared to the
pre-MELD era translates to a very high mortality in this
group of patients.
The higher incidence of new-onset post-LT ESRD in the
MELD era may represent the tip of the iceberg. We spec-
ulate that the development of post-LT Stage 4 chronic kid-
ney disease has likely, also increased in the MELD era.
This suggests that many additional cases of post-LT ESRD
will be revealed over time and may add to already skyrock-
eting healthcare cost in terms of additional dialysis cases,
and increased hospitalization rates secondary to morbidi-
ties associated with ESRD.
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Table 2: Recipient and donor risk factors associated with new-
onset post-LT ESRD in the MELD era
Hazard ratio
Variables (95% CI) p-Value
Recipient factors
Age 18–29 years (ref: 50–59 years) 0.56 (0.32–0.99) 0.046
African American (ref: white) 1.57 (1.3–1.9) <0.0001
Cholestatic (ref: noncholestatic) 0.64 (0.47–0.88) 0.006
HCV (ref: non-HCV) 1.34 (1.15–1.58) 0.0003
Recipient diabetes 2.20 (1.92–2.52) <0.0001
Ln Creatinine 4.08 (3.6–4.6) <0.0001
Creatinine slope 0.86 (0.81–0.91) <0.0001
Ln Bilirubin 0.83 (0.77–0.90) <0.0001
Ln Albumin 0.53 (0.42–0.68) <0.0001
Sodium >141 mmol/L/l 1.42 (1.12–1.79) 0.0034
(Ref: 130–141)
TIPS recipients 1.40 (1.14–1.71) 0.0013
Previous LT 1.49 (1.17–1.89) 0.0012
Donor factors
Donor age (ref: 30–39)
50–59 years 1.27 (1.07–1.52) 0.0074
60–69 years 1.29 (1.05–1.60) 0.018
Donor female (ref: male) 0.86 (0.76–0.98) 0.027
Cold ischemia time (per hour) 1.03 (1.01–1.04) 0.0004
DCD (ref: non-DCD) 1.47 (1.10–1.97) 0.0098
HCV = hepatitis C; LT = liver transplant; DCD = donation after
cardiac death.
Pre-LT serum creatinine was one of the strongest predic-
tors of post-LT ESRD in our study. Because creatinine is
heavily weighted in the MELD equation currently used for
allocation (2), the MELD era has been characterized by
a significantly higher proportion of candidates undergoing
LT with serum creatinine ≥2 mg/dL compared to the pre-
MELD era (3). This has increased the number of recipients
at high risk for new-onset post-LT ESRD.
Interestingly, a steeper slope of creatinine during the in-
terval from the time of listing to LT was associated with a
lower risk of post-LT ESRD. A plausible explanation for this
observation is that a rapid rise in creatinine before LT may
represent an acute renal injury secondary to hepatorenal
syndrome, which would be expected to improve after suc-
cessful LT. Conversely, candidates with a more gradual rise
in creatinine are more likely to have preexisting structural
renal disease, which may progress to post-LT ESRD over
time.
In addition to previously identified risk factors for new-
onset post-LT ESRD such as African American race, history
of pre-LT diabetes and high pre-LT creatinine (1,10–13),
our study also showed that serum sodium >141 mmol/L,
lower albumin, lower bilirubin, history of TIPS and previ-
ous LT were each significantly and independently associ-
ated with new-onset post-LT ESRD. Lower albumin levels
and history of TIPS represent an advanced stage of cirrho-
sis. High serum sodium may represent a volume-depleted
state, whereas low serum sodium is often associated with
potentially reversible hepatorenal syndrome.
Our analysis did not identify gender as a predictor of ESRD
risk following LT. The degree to which creatinine under-
states ESRD risk among females may not have been of
sufficient magnitude to produce an independently signif-
icant gender effect. Also, the degree to which creatinine
understates ESRD risk may be lower in post-LT patients.
Our study also showed that a diagnosis of hepatitis C
and noncholestatic liver disease were associated with a
higher risk of post-LT ESRD compared to nonhepatitis C
and cholestatic liver disease, respectively. Hepatitis C is
a frequent diagnosis among noncholestatic liver disease
patients and a lower bilirubin level is commonly seen in
noncholestatic liver disease. The number of candidates
listed and transplanted for hepatitis C has increased over
time (14,15). Candidates with hepatitis C may have preex-
isting intrinsic kidney disease, secondary to membranous
or membrano-proliferative glomerulonephritis, which may
eventually progress to post-LT ESRD.
Various donor factors such as advanced age (≥50 years),
male gender, prolonged cold ischemia time and DCD donor
type were associated with a higher risk of post-LT ESRD.
These donor factors have also been shown to be associ-
ated with poor graft survival (16).
The primary limitation of our study is the retrospective ob-
servational study design that may result in the potential
for bias due to patient selection and unmeasured patient
characteristics. Moreover, this study was unable to eval-
uate the causes of post-LT ESRD because of the lack of
renal biopsy and urinalysis information in SRTR data. An
additional limitation is unavailable or missing data on cre-
atinine, bilirubin and INR from the pre-MELD era, which
could have been used to determine whether the adverse
effects of these covariates on post-LT ESRD varied by al-
location era. Despite these limitations, this is the largest
cohort study from the MELD era to evaluate the impact
of current liver allocation policy on post-LT ESRD. The pri-
mary outcome of our study was new-onset post-LT ESRD,
as opposed to chronic renal failure which was used in pre-
vious studies (1,4). Post-LT ESRD is more reliably tracked
and ascertained than Stage 4 chronic kidney disease.
In conclusion, our study has demonstrated that the risk of
new-onset ESRD among LT recipients is markedly higher
in the MELD era. The risk of post-LT ESRD, which had
been declining before the implementation of MELD-based
allocation, has increased by 7.6% per year, since its in-
troduction in 2002. Because the development of ESRD
is associated with very high mortality among LT recip-
ients, risk modification directed toward optimizing renal
function may be useful in the pre, peri and postoperative
management of LT candidates and may prevent or delay
post-LT ESRD. These measures may have a significant
downstream effect on decrease in the need for dialysis,
post-LT ESRD related mortality, need for renal transplanta-
tion and healthcare cost. Finally, reweighting of creatinine
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Table 3: Predictors of post-LT mortality
Variables Hazard ratio 95% CI p-Value
Post-LT ESRD (time dependent) 3.32 2.96–3.71 <0.0001
Age 18–29 years (ref: age 50–59 years) 0.85 0.72–1.00 0.0429
30–39 0.80 0.71–0.91 0.0009
40–49 0.88 0.82–0.94 0.0001
60–64 1.18 1.09–1.27 <0.0001
65 and above 1.40 1.29–1.52 <0.0001
African American (ref: white) 1.25 1.15–1.36 <0.0001
Hispanic 0.86 0.79–0.93 0.0003
Asian 0.80 0.70–0.92 0.0012
Hepatitis C (ref: non-HCV) 1.39 1.31–1.48 <0.0001
HCC (ref: non-HCC) 1.34 1.25–1.44 <0.0001
Pre-LT DM (ref: no DM) 1.18 1.11–1.25 <0.0001
Ln Creatinine at LT 1.13 1.07–1.20 <0.0001
Ln Albumin at LT 0.73 0.66–0.81 <0.0001
Hospitalized ICU (ref: ambulatory) 1.34 1.20–1.50 <.0001
Hospitalized non ICU 1.16 1.07–1.25 0.0001
Mechanical life support at LT (ref: no mechanical life support) 1.58 1.40–1.79 <0.0001
Status 1 (ref: non-status 1) 0.74 0.64–0.85 <0.0001
Repeat LT (ref: no) 1.70 1.54–1.87 <0.0001
Portal vein thrombosis (ref: none) 1.39 1.25–1.56 <0.0001
Donor age 0–17 (ref: 18–39) 0.90 0.81–1.003 0.0571
40–49 1.20 1.12–1.29 <0.0001
50–59 1.32 1.23–1.42 <0.0001
60–69 1.58 1.46–1.72 <0.0001
70 and above 1.71 1.53–1.90 <0.0001
Cold ischemia time 1.01 1.004–1.02 0.0030
DCD (ref: no) 1.25 1.10–1.43 0.0006
Regional (ref: local) 1.03 0.97–1.10 0.2893
National 1.16 1.05–1.28 0.0034
in theMELD formula should be considered (2). Thismodest
modification to the allocation system may balance the de-
sire to improve overall post-LT outcomes while reducing
the risk of renal failure and reducing wait-list mortality.
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